29.45 0.00 (0.00%)
After hours: 5:08PM EDT
|Bid||29.45 x 300|
|Ask||29.50 x 100|
|Day's Range||29.20 - 29.68|
|52 Week Range||24.54 - 29.93|
|PE Ratio (TTM)||387.50|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.84|
On April 25, Thermo Fisher Scientific (TMO) announced its earnings results for 1Q18, which ended on March 31. Its revenues grew ~23% to ~$5.9 billion YoY (year-over-year). The sales results came in ahead of analysts’ estimate of ~$5.6 billion.
On April 25, Boston Scientific announced its 1Q18 earnings results. Boston Scientific’s results exceeded analysts’ estimates and the company guidance. During the earnings release, Boston Scientific updated its outlook for fiscal 2018. The company expects to register fiscal 2018 sales of $9.75 billion–$9.9 billion. The EPS (earnings per share) in fiscal 2018 is expected to be $1.37–$1.41.
Boston Scientific rose Wednesday after quarterly sales and adjusted profit beat, but investors are still waiting for an update on its heart valves.
Boston Scientific Corp raised its full-year forecast on Wednesday after reporting stronger-than-expected growth across its businesses, soothing fears that it was losing share in the lucrative market for heart valves. The company, which lags behind Medtronic Plc and Edwards Lifesciences Corp in the heart valves market, is pinning its hopes on its updated Lotus device, set for launch in 2019, following the withdrawal of an earlier version from Europe last year.
For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...
Boston Scientific Corp. (BSX) on Wednesday reported first-quarter net income of $298 million. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 21 cents. Earnings, ...
U.S. medical device maker Boston Scientific Corp reported a 10 percent rise in first-quarter net sales on Wednesday, helped by higher demand for its products, including pacemakers and heart valves. Net ...
MARLBOROUGH, Mass. , April 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.379 billion during the first quarter ended March 31, 2018. This represents growth of ...
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.
In 1Q18, Boston Scientific (BSX) is expected to report adjusted EPS (earnings per share) of $0.32, representing YoY (year-over-year) growth of ~8.7%. The company reported adjusted EPS of $0.34 in fiscal 4Q17, and it had registered YoY growth of ~14.8%. The adjusted EPS were in line with Wall Street expectations.
MARLBOROUGH, Mass., April 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of deep brain stimulation (DBS) for advanced, levodopa-responsive Parkinson's disease (PD) in the United States. The study is a late-breaking emerging science session presentation at today's meeting of the 70th Annual American Academy of Neurology Meeting in Los Angeles.
On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31. According to Wall Street analysts’ estimates, the company’s 1Q18 revenues are expected to come in at $2.34 billion, representing YoY (year-over-year) growth of ~8.4%.
The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
Stock Monitor: CHF Solutions Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX ). If ...
San Bruno-based nVision makes a microcatheter device used to screen for ovarian cancer and was founded by a 32-year-old female CEO who was honored last year as a distinguished alumnus of the Harker School in San Jose. She had raised only $17 million in venture funding before the sale.
Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.
The '550 patent was the only Edwards patent that Boston Scientific was found to infringe in the March 2017 German District Court litigation between the companies and is also the sole basis of Edwards' infringement action against Boston Scientific in Ireland. While Edwards has the right to appeal the EPO's decision, Boston Scientific believes the Edwards patent revocation will have a positive impact on both suits.
Surbhi Sarna decided she wanted to start a woman's health company after she suffered from an ovarian cyst so painful she passed out at age 15. Now she is 32, and her company is being bought by Boston Scientific.
MARLBOROUGH, Mass., April 16, 2018 /PRNewswire/ -- Boston Scientific (BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women's health. Ovarian cancer is the fifth leading cause of cancer death among women.